SK288118B6 - Pharmaceutical form of administration, methods for its production and use - Google Patents

Pharmaceutical form of administration, methods for its production and use Download PDF

Info

Publication number
SK288118B6
SK288118B6 SK1716-2002A SK17162002A SK288118B6 SK 288118 B6 SK288118 B6 SK 288118B6 SK 17162002 A SK17162002 A SK 17162002A SK 288118 B6 SK288118 B6 SK 288118B6
Authority
SK
Slovakia
Prior art keywords
acid
dosage form
cetrorelix
acetate
form according
Prior art date
Application number
SK1716-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK17162002A3 (sk
Inventor
Horst Bauer
Michael Damm
Werner Sarlikiotis
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of SK17162002A3 publication Critical patent/SK17162002A3/sk
Publication of SK288118B6 publication Critical patent/SK288118B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1716-2002A 2000-05-18 2001-05-16 Pharmaceutical form of administration, methods for its production and use SK288118B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10024451A DE10024451A1 (de) 2000-05-18 2000-05-18 Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
PCT/EP2001/005555 WO2001087265A2 (de) 2000-05-18 2001-05-16 Pharmazeutische darreichungsform für peptide, verfahren zu deren herstellung und verwendung

Publications (2)

Publication Number Publication Date
SK17162002A3 SK17162002A3 (sk) 2003-07-01
SK288118B6 true SK288118B6 (sk) 2013-09-03

Family

ID=7642584

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1716-2002A SK288118B6 (sk) 2000-05-18 2001-05-16 Pharmaceutical form of administration, methods for its production and use

Country Status (25)

Country Link
US (2) US7718599B2 (hu)
EP (1) EP1282400B1 (hu)
JP (2) JP4944340B2 (hu)
KR (1) KR100580142B1 (hu)
CN (1) CN100342908C (hu)
AR (1) AR028588A1 (hu)
AU (1) AU777185B2 (hu)
BG (1) BG65976B1 (hu)
BR (1) BR0110892A (hu)
CA (1) CA2348167C (hu)
CZ (1) CZ303981B6 (hu)
DE (1) DE10024451A1 (hu)
HK (1) HK1058622A1 (hu)
HU (1) HUP0302050A3 (hu)
IL (1) IL152479A (hu)
MX (1) MXPA02011389A (hu)
NO (1) NO20025277D0 (hu)
NZ (1) NZ522381A (hu)
PL (1) PL203958B1 (hu)
RU (1) RU2253438C2 (hu)
SK (1) SK288118B6 (hu)
TW (1) TWI243059B (hu)
UA (1) UA74578C2 (hu)
WO (1) WO2001087265A2 (hu)
ZA (1) ZA200208761B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
JP4940492B2 (ja) * 2000-09-04 2012-05-30 大正製薬株式会社 鉄化合物配合内服液剤
DE10157628A1 (de) * 2001-11-26 2003-06-12 Zentaris Ag Injektionslösung eines LHRH-Antagonisten
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
DK1565160T3 (da) * 2002-09-27 2014-04-28 Terna Zentaris Gmbh Administrationsform til farmaceutisk aktive peptider med vedvarende frigivelse og en fremgangsmåde til fremstilling deraf
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
ATE381945T1 (de) * 2004-03-12 2008-01-15 Intercell Ag Verfahren zur solubilisierung von peptid- mischungen
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006110118A1 (fr) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Produit cytoprotecteur
WO2006110119A1 (fr) * 2005-04-15 2006-10-19 Victor Pavlovich Kutnyak Produit antineoplasique (et variantes)
WO2012077131A1 (en) * 2010-12-06 2012-06-14 Astron Research Limited A stable ready-to-use cetrorelix injection
CN102144980B (zh) * 2011-03-07 2013-01-09 深圳市健元医药科技有限公司 一种更加稳定的lhrh拮抗剂冻干粉针剂
CN106456704A (zh) * 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
CA3052157A1 (en) * 2017-01-31 2018-08-09 Veru Inc. Compositions and methods for long term release of ganadotropin-releasing hormone (gnrh) antagonists
US20220233631A1 (en) 2019-06-17 2022-07-28 Intas Pharmaceuticals Ltd. Stable formulation of cetrorelix
US20210121517A1 (en) 2019-10-24 2021-04-29 Sun Pharmaceutical Industries Limited Stable parenteral dosage form of cetrorelix acetate
EP4164608A1 (en) 2021-06-25 2023-04-19 Extrovis AG Pharmaceutical compositions
WO2023017326A1 (en) * 2021-08-11 2023-02-16 Rk Pharma Inc. Ready to use compositions of cetrorelix acetate

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE141996C (hu)
DD141996A1 (de) * 1979-02-21 1980-06-04 Ingrid Wolf Verfahren zur herstellung von lyophilisierten lhrh-praeparationen
JPS5892620A (ja) * 1981-11-28 1983-06-02 Sunstar Inc インタ−フエロン安定配合組成物
US4565804A (en) * 1984-09-07 1986-01-21 The Salk Institute For Biological Studies GnRH Antagonists VI
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
DK163689A (da) * 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
JPH0725662B2 (ja) * 1990-10-22 1995-03-22 アース製薬株式会社 使用時調製型上皮細胞成長因子含有水性薬剤の安定化方法
US5643878A (en) * 1991-09-12 1997-07-01 Ciba-Geigy Corporation 5-amino-4-hydroxyhexanoic acid derivatives
JP3608802B2 (ja) * 1991-09-20 2005-01-12 第一サントリーファーマ株式会社 安定なカルシトニン医薬組成物及びその製造法
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
WO1994008605A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Corporation Therapeutic microemulsions
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4305225A1 (de) 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
JP3636480B2 (ja) * 1993-05-19 2005-04-06 科研製薬株式会社 凍結乾燥製剤
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
JP2915296B2 (ja) * 1993-08-30 1999-07-05 宇野 潤 抗真菌製剤
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
ES2151079T3 (es) * 1994-09-09 2000-12-16 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida que contiene una sal metalica de un peptido.
MY129435A (en) * 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
EP0726075A1 (en) * 1995-02-08 1996-08-14 Therapicon Srl Pharmaceutical non-inorganic saline solutions for endonasal administration
CA2214889C (en) 1995-03-10 2005-05-24 Hans Koll Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and a process for the production thereof
DE19542837A1 (de) * 1995-11-17 1997-05-22 Boehringer Mannheim Gmbh Polypeptid-enthaltende pharmazeutische Darreichungsformen in Form von Mikropartikeln und Verfahren zu deren Herstellung
US5942493A (en) 1995-11-28 1999-08-24 Asta Medica Aktiengesellschaft LH-RH antagonists having improved action
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
IT1282733B1 (it) * 1996-05-20 1998-03-31 Flarer S A Composizioni farmaceutiche contenenti ciclosporina ed un veicolante comprendente almeno un estere dell'acido alfa-glicerofosforico
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
AU6141498A (en) * 1997-02-04 1998-08-25 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
DE19712718C2 (de) * 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
AU7904998A (en) * 1997-07-07 1999-02-08 Peptichemio Ag Pharmaceutical composition containing peptichemio
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
EP1952820A3 (en) * 1998-03-06 2012-06-20 Chugai Seiyaku Kabushiki Kaisha Protein-free G-CSF formulations
WO2000015241A1 (fr) * 1998-09-11 2000-03-23 Chugai Seiyaku Kabushiki Kaisha Preparation d'une solution proteinique et son procede de stabilisation
EP0998940A1 (en) * 1998-09-30 2000-05-10 Laboratoire Theramex Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues
DE19911771B4 (de) 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US6911455B2 (en) * 1999-12-22 2005-06-28 Smithkline Beecham Corporation Methods for preparing pharmaceutical formulations

Also Published As

Publication number Publication date
AU777185C (en) 2001-11-26
IL152479A (en) 2013-08-29
RU2253438C2 (ru) 2005-06-10
ZA200208761B (en) 2002-11-29
US7696149B2 (en) 2010-04-13
SK17162002A3 (sk) 2003-07-01
AR028588A1 (es) 2003-05-14
DE10024451A1 (de) 2001-11-29
EP1282400B1 (de) 2016-12-14
CZ303981B6 (cs) 2013-07-31
UA74578C2 (uk) 2006-01-16
US7718599B2 (en) 2010-05-18
AU7404101A (en) 2001-11-26
JP2003533466A (ja) 2003-11-11
CA2348167A1 (en) 2001-11-18
US20050159335A1 (en) 2005-07-21
US20020039996A1 (en) 2002-04-04
CZ20023969A3 (cs) 2003-05-14
KR20030036179A (ko) 2003-05-09
NO20025277L (no) 2002-11-04
BG107312A (bg) 2003-06-30
MXPA02011389A (es) 2003-04-25
NZ522381A (en) 2004-07-30
HK1058622A1 (en) 2004-05-28
JP4944340B2 (ja) 2012-05-30
IL152479A0 (en) 2003-05-29
BG65976B1 (bg) 2010-08-31
NO20025277D0 (no) 2002-11-04
CA2348167C (en) 2012-01-10
PL203958B1 (pl) 2009-11-30
HUP0302050A3 (en) 2012-11-28
BR0110892A (pt) 2003-03-11
JP2011213733A (ja) 2011-10-27
HUP0302050A2 (hu) 2003-09-29
WO2001087265A3 (de) 2002-04-18
KR100580142B1 (ko) 2006-05-16
TWI243059B (en) 2005-11-11
PL363007A1 (en) 2004-11-15
CN1469734A (zh) 2004-01-21
AU777185B2 (en) 2004-10-07
CN100342908C (zh) 2007-10-17
EP1282400A2 (de) 2003-02-12
WO2001087265A2 (de) 2001-11-22

Similar Documents

Publication Publication Date Title
SK288118B6 (sk) Pharmaceutical form of administration, methods for its production and use
CA2474698C (en) Polymer-based compositions for sustained release
JP3698721B2 (ja) 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
EP1928413A1 (en) Hfsh aqueous formulation
IL167415A (en) Form of delivery with delayed release of pharmaceutically active peptides and method of production
JP2006137678A (ja) インターロイキン−２組成物
US6025396A (en) Stable prostaglandin E1-containing injectable composition
JP4142149B2 (ja) バンコマイシンの凍結乾燥製剤
SK7262003A3 (en) Pharmaceutical dronedarone composition for parenteral administration
JP4343693B2 (ja) Ｌｈｒｈアンタゴニストの注入溶液
KR100661768B1 (ko) 펩타이드성 화합물과 담체 거대분자를 포함하는 약제학적 조성물의 제조방법 및 이로부터 제조된 약제학적 조성물
JP2002508330A (ja) ダルホプリスチンおよびキヌプリスチンに基づく医薬組成物ならびに調製

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20170516